| Name | Title | Contact Details |
|---|---|---|
Chandra Pydi |
Vice President, IT Portfolio Management | Profile |
Chris Walzer |
Vice President & CIO, SPMR | Profile |
Kallie Smith |
Director, Cyber Security at McKesson | Profile |
Tiffany Chisum |
Director of Information Security | Profile |
Olanrewaju Oluleye |
Senior Manager, Cyber Fraud Defense | Profile |
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
TubeWriter is a company that provides direct labeling systems and services to the life sciences industry. Their solutions print on any laboratory tube, slide or plate, and offer superior durability of print at extreme temperatures, up to 90% reduction ...
Developing HIV prevention products for women worldwide
Angstrom Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our local centers provide infusion care such as Remicade, Ocrevus, and Entyvio and injections like Xolair and Fasenra for patients with ongoing conditions.